Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.

CompletadoFase 4ClinicalTrials.gov

ID: NCT00337662Tipo: INTERVENTIONALInicio: 1 de may de 2006Fin estimado: 1 de dic de 2007

Traducción no disponible, mostrando original

Resumen

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 65 YearsSexo: ALL

Criterios de inclusión

Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.
Patients must have experienced an exacerbation of their illness within the previous 2 weeks.
Patients in whom a switch to another antipsychotic medication is acutely indicated.

Criterios de exclusión

Patients who are deemed nonresponsive to risperidone or olanzapine.
Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.
Patients having received olanzapine or risperidone in the past 30 days.
Treatment with clozapine within 1 year prior to Visit 1.
Diagnosis of substance-induced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).
A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.

Intervenciones

drug

olanzapine

10-20 milligrams (mg), oral, daily, 10 weeks.

drug

risperidone

2-6 mg, oral, daily, for 10 weeks.

drug

risperidone

2-6 mg, oral, daily, 10 weeks

Ubicaciones

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Buenos Aires, Argentina

Patrocinadores

PrincipalEli Lilly and Company

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Predicting Response to Risperidone Treatment Through Iden... | EligiMed